This study confirmed the presence of an LCSC subpopulation with a CD133+EpCAM+ phenotype in the tumors and blood of patients with lung cancer, and these results suggest an important role for CD133 and EpCAM in lung cancer progression and their potential application as novel biomarkers of the disease. Here, PROM1 is linked to lung carcinoma.